Hormonal
SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) significantly reduce cardiovascular mortality and heart failure hospitalization in type 2 diabetes patients, while also reducing liver fat content and improving liver enzymes in those with MASLD.
If you have Type 2 Diabetes and fatty liver disease, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs are proven to significantly lower your risk of heart failure and death, and they also help reduce fat in your liver. They are a key part of modern care for this condition.
In the EMPA-REG OUTCOME trial, empagliflozin significantly reduced cardiovascular mortality by 38%, hospitalization for heart failure by 35%, and all-cause mortality by 32% compared with placebo... Beyond cardiovascular outcomes, the E-LIFT trial demonstrated that empagliflozin reduced liver fat content and improved aminotransferases in patients with T2D and MASLD.
Why this rating
Supported by large randomized trials (EMPA-REG, CANVAS) and specific MASLD trials (E-LIFT, EFFECT II), though histological fibrosis data is noted as lacking.
Source
Cardiovascular Health in the Shadow of Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease: An Emerging Paradigm
Alfredo Caturano et al. · Reviews in Cardiovascular Medicine · 2025
DOI 10.31083/rcm43143
More from this paper
- GLP-1 receptor agonists (liraglutide, semaglutide, dulaglutide) reduce major adverse cardiovascular events (MACE) and promote histological resolution of MASH in patients with T2D and MASLD.Good
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, achieves superior weight loss and hepatic steatosis reduction compared to semaglutide, with preliminary cardiovascular non-inferiority data.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →